Anti-viral developer Alios raises $8M more for $32M
Alios BioPharma, developer of anti-viral therapies, has tacked $8 million onto its first round of funding, bringing its total to $32 million. The new money came solely from SR One. Based in South San Francisco, the company plans to use the money to push its lead compound past phase-one trials.
Alios brought in the initial $24 million from Novartis Ventures, Novo AS and Roche Venture Fund.
Alios nabs $8.4M to treat viruses
South San Francisco-based Alios BiopPharma just brought in $8.4 million in first-round funding from Novo, Novartis BioVentures and Roche Finance, according to peHUB. The company develops treatments for viruses by activating various parts of the normal human immune system.